Ekso Bionics Holdings GAAP EPS of -$0.29, revenue of $41.5M beats by $23.4M (CHRN:NASDAQ)

Ekso Bionics Holdings reported Q1 GAAP EPS of -$0.29 and revenue of $41.5M, exceeding estimates by $23.4M. Revenue grew 1127.8% year-over-year. Adjusted EBITDA was $5.9M, down from $9.4M in the prior year quarter.

Original reporting
Published Oct 15, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CHRN
Neutral
medium confidence
Mentioned
$CHRN
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CHRNNeutralMed
01

Why it matters

The earnings release provides the first public data on Q1 performance, offering traders fresh information to assess valuation.

02

Market read

First‑report earnings for a micro‑cap biotech; relevance driven by revenue surprise rather than profitability.

03

What to watch

Potential upcoming regulatory approvals or partnership announcements could change outlook.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

Ekso Bionics is a developer of wearable exoskeletons for medical and industrial use.

Company-level read

Ticker impact

$CHRNNeutralMedium confidence
Context

Q1 GAAP EPS of -$0.29 and revenue of $41.5M, a 1127.8% YoY increase, beating estimates by $23.4M.

Expected impact

likely modest downside as investors weigh loss against revenue growth

Evidence & confidence

Loss per share signals ongoing cost issues, but the revenue surge could attract upside speculation.

Market effects

Highlights rapid growth potential in the exoskeleton/medical device sector.

Limited to U.S. small‑cap investors; no broader regional effect.

Minimal global impact beyond niche biotech/medtech investors.

Counterpoint

Revenue beat may be unsustainable; focus on cash burn and loss per share.

Key entities

  • Ekso Bionics Holdings

    Publicly traded exoskeleton manufacturer (NASDAQ: CHRN).

Related articles

$SLNHMed

Soluna and Applied Digital to build 50 MW wind-powered AI data center in Texas

Soluna (SLNH) and Applied Digital (APLD) agreed to form a joint venture to build a 50 MW wind-powered AI data center in Texas. Applied will own 51%, providing capital, while Soluna contributes land and power assets. ChronoScale (CHRN), majority-owned by Applied, may lease the facility. The project is expected to close by year-end, with Phase 1 powered by Soluna's Briscoe Wind Farm and the grid.

$CHRNMedAI 8/10

ChronoScale Reports Fiscal First Quarter 2027 Results

ChronoScale Holdings Corp (CHRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ChronoScale Reports Fiscal First Quarter 2027 Results MENLO PARK, Calif. – October 15, 2026 — ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence

$CHRNMed

ChronoScale Expands AI Pipeline With $1 Billion Revenue Run Rate In Sight

ChronoScale Holdings (CHRN) shares rose after expanding AI infrastructure contracts, projecting a $1 billion annualized revenue run rate by Q3 2027. The company also completed the sale of its Ekso Bionics business. CHRN is trading at $20.33, above its 20-day and 100-day SMAs but below the 50-day SMA. Analysts rate CHRN as Strong Buy with an average price target of $32.

$CHRNHighAI 8/10

ChronoScale stock jumps on $1B revenue target from AI deals

ChronoScale Corp (CHRN) shares rose 3% after-hours after announcing deals expected to reach $1B annualized revenue run rate by Q3 2027. The AI infrastructure provider signed a contract extension and new customer agreement, though revenue is subject to deployment and capital risks. The company also sold its Ekso Bionics unit to focus on core AI infrastructure business.